Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2016-06-23
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of alisertib when given together
with abiraterone acetate and prednisone and to see how well it works in treating patients
with hormone-resistant prostate cancer. Alisertib and abiraterone acetate may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause
the growth of prostate cancer cells. Drugs, such as abiraterone acetate, may also lessen the
amount of androgens made by the body. Drugs used in chemotherapy, such as prednisone, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving alisertib, abiraterone acetate, and prednisone together may be an
effective treatment for prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University